-
公开(公告)号:US11891365B2
公开(公告)日:2024-02-06
申请号:US17238321
申请日:2021-04-23
申请人: Valo Health, Inc.
发明人: Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Heather Davis , Aleksandra Rudnitskaya , David R. Lancia, Jr. , Kenneth W. Bair , David S. Millan , Matthew W. Martin
IPC分类号: A61K31/5513 , C07D267/14 , C07D291/08 , C07D413/06 , C07D419/06 , C07D413/12 , C07D413/04 , C07D267/12 , C07D243/14 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D417/04 , C07D471/04 , C07D498/04 , C07D498/08 , C07D493/08 , C07D413/08 , C07D491/107 , C07D495/10
CPC分类号: C07D267/14 , C07D243/14 , C07D267/12 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/04 , C07D413/06 , C07D413/08 , C07D413/12 , C07D413/14 , C07D417/04 , C07D471/04 , C07D491/107 , C07D493/08 , C07D495/10 , C07D498/04 , C07D498/08
摘要: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I:
where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.-
公开(公告)号:US11279681B2
公开(公告)日:2022-03-22
申请号:US17031814
申请日:2020-09-24
申请人: Valo Health, Inc.
发明人: Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, Jr. , David S. Millan , Matthew W. Martin , Kenneth W. Bair
IPC分类号: A61K31/55 , A61K31/554 , C07D223/16 , C07D281/02 , C07D281/10 , C07D471/04 , C07D513/04 , C07D267/14 , C07D413/06 , C07D413/12 , C07D413/04 , C07D267/12 , C07D243/14 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D417/04 , C07D498/04 , C07D498/08 , C07D493/08 , C07D413/08 , C07D491/107 , C07D495/10
摘要: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
公开(公告)号:US20230406830A1
公开(公告)日:2023-12-21
申请号:US18096712
申请日:2023-01-13
申请人: Valo Health, Inc.
发明人: Xiaozhang Zheng , Pui Yee Ng , Jennifer R. Downing , Mary-Margaret Zablocki , Bingsong Han , Nicholas Barczak , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, JR. , Kenneth W. Bair
IPC分类号: C07D265/36 , C07D413/12 , C07D413/06 , C07D401/04 , C07D279/16 , C07D491/107 , C07D413/10 , C07D471/04 , C07D417/06 , C07D513/04 , C07D487/04 , C07D265/34 , C07D279/14
CPC分类号: C07D265/36 , C07D413/12 , C07D413/06 , C07D401/04 , C07D279/16 , C07D491/107 , C07D413/10 , C07D471/04 , C07D417/06 , C07D513/04 , C07D487/04 , C07D265/34 , C07D279/14
摘要: The present invention is directed to compounds of Formula I:
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2′, L, X, W, Y1, Y2, Y3, and Y4 are described herein.-
公开(公告)号:US11345672B2
公开(公告)日:2022-05-31
申请号:US16688469
申请日:2019-11-19
申请人: Valo Health, Inc.
发明人: Jennifer Lee , Nicholas Barczak , Jaime A. Escobedo , Chiara Conti , Bingsong Han , David R. Lancia, Jr. , Cuixian Liu , Matthew W. Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R. Thomason , Xiaozhang Zheng
IPC分类号: C07D263/58 , A61P35/00 , A61K31/403 , A61K31/404 , A61K31/4178 , A61K31/4184 , A61K31/4188 , A61K31/4192 , A61K31/422 , A61K31/423 , A61K31/4245 , A61K31/427 , A61K31/428 , A61K31/435 , A61K31/437 , A61K31/438 , A61K31/4439 , A61K31/4709 , A61K31/4985 , A61K31/506 , A61K31/52 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07C53/06 , C07D209/40 , C07D209/54 , C07D221/20 , C07D235/30 , C07D277/82 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/06 , C07D405/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D473/00 , C07D487/04 , C07D491/056 , C07D491/107 , C07D498/04
摘要: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.
-
公开(公告)号:US11274085B2
公开(公告)日:2022-03-15
申请号:US17031815
申请日:2020-09-24
申请人: Valo Health, Inc.
发明人: Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, Jr. , David S. Millan , Matthew W. Martin
IPC分类号: A61K31/55 , A61K31/554 , C07D223/16 , C07D281/02 , C07D281/10 , C07D471/04 , C07D513/04 , C07D267/14 , C07D413/06 , C07D413/12 , C07D413/04 , C07D267/12 , C07D243/14 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/14 , C07D417/04 , C07D498/04 , C07D498/08 , C07D493/08 , C07D413/08 , C07D491/107 , C07D495/10
摘要: The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
公开(公告)号:US20230414585A1
公开(公告)日:2023-12-28
申请号:US18215887
申请日:2023-06-29
申请人: Valo Health, Inc.
IPC分类号: A61K31/438 , C07D401/04 , C07D221/20 , C07D401/06 , C07D209/54
CPC分类号: A61K31/438 , C07D401/04 , C07D221/20 , C07D401/06 , C07D209/54 , A61P25/14
摘要: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
-
公开(公告)号:US20230242512A1
公开(公告)日:2023-08-03
申请号:US17984065
申请日:2022-11-09
申请人: Valo Health, Inc.
发明人: Xiaozhang Zheng , Matthew W. Martin , Pui Yee Ng , Jennifer R. Thomason , Bingsong Han , Aleksandra Rudnitskaya , David R. Lancia, JR.
IPC分类号: C07D403/04 , C07D209/10 , C07D209/44 , C07D401/04 , C07D401/12 , C07D413/04 , C07D413/12 , C07D417/04 , C07D471/04 , C07D498/04 , C07D513/04
CPC分类号: C07D403/04 , C07D209/10 , C07D209/44 , C07D401/04 , C07D401/12 , C07D413/04 , C07D413/12 , C07D417/04 , C07D471/04 , C07D498/04 , C07D513/04
摘要: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs), having the formula:
wherein Z, X1, X2, Y1, Y2, Y3, L, Z, and R are described herein.-
公开(公告)号:US11702412B2
公开(公告)日:2023-07-18
申请号:US17124778
申请日:2020-12-17
申请人: Valo Health, Inc.
IPC分类号: C07D267/22 , C07D413/06 , C07D498/04 , A61P19/02 , A61P25/28 , A61P35/00
CPC分类号: C07D413/06 , C07D267/22
摘要: The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II:
where R, L, X1, X2, X3, X4, X5, Y1, Y2, Y3, and Y4 are described herein.-
公开(公告)号:US11414392B2
公开(公告)日:2022-08-16
申请号:US17066385
申请日:2020-10-08
申请人: Valo Health, Inc.
发明人: Xiaozhang Zheng , Pui Yee Ng , Jennifer R. Thomason , Mary-Margaret Zablocki , Bingsong Han , Nicholas Barczak , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, Jr. , Kenneth W. Bair
IPC分类号: C07D265/36 , C07D413/12 , C07D413/06 , C07D401/04 , C07D279/16 , C07D491/107 , C07D413/10 , C07D471/04 , C07D417/06 , C07D513/04 , C07D487/04 , C07D265/34 , C07D279/14
摘要: The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2′, L, X, W, Y1, Y2, Y3, and Y4 are described herein.
-
公开(公告)号:US20220204461A1
公开(公告)日:2022-06-30
申请号:US17691186
申请日:2022-03-10
申请人: Valo Health, Inc.
发明人: Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, JR. , David S. Millan , Matthew W. Martin
IPC分类号: C07D267/14 , C07D498/08 , C07D267/12 , C07D291/08 , C07D401/06 , C07D401/10 , C07D403/06 , C07D403/10 , C07D405/06 , C07D413/04 , C07D413/06 , C07D413/08 , C07D413/12 , C07D413/14 , C07D417/04 , C07D471/04 , C07D491/107 , C07D493/08 , C07D495/10 , C07D498/04 , C07D243/14
摘要: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
-
-
-
-
-
-
-
-
-